Torisel’s Positive Effect on Overall Survival Expected To Drive Sales
Executive Summary
Wyeth is projecting that Torisel will capture a 25 percent share of the global renal cell carcinoma market within three years following its July launch
You may also be interested in...
Novartis Speeds RAD001 Filing Schedule After Presenting RECORD-1 At ASCO
CHICAGO - With data in hand showing RAD001 (everolimus) doubled progression-free survival in metastatic kidney cancer, Novartis is accelerating its submission schedule and plans to file for the indication by July for a possible 2009 launch of its mTOR inhibitor for oncology
Novartis Speeds RAD001 Filing Schedule After Presenting RECORD-1 At ASCO
CHICAGO - With data in hand showing RAD001 (everolimus) doubled progression-free survival in metastatic kidney cancer, Novartis is accelerating its submission schedule and plans to file for the indication by July for a possible 2009 launch of its mTOR inhibitor for oncology
Lybrel, Torisel launches underway
Wyeth is shipping its May approvals in earnest beginning this month, firm says during a July 19 earnings call. Launches of continuous oral contraceptive Lybrel (levonorgestrel/ethinyl estradiol) and renal cell carcinoma treatment Torisel (temsirolimus) are the first of seven launches planned for the next 18 months, Chief Operating Officer Bernard Poussot says. Promotional materials are being finalized and active promotion will begin shortly, Poussot adds (1"The Pink Sheet" June 4, 2007, p. 3)...